ACVR2A and obesity disorder: Sotatercept, an ActRIIA-Fc that has been FDA-approved for PAH and has been shown to have anti-inflammatory and anti-proliferative effects on vascular cells[173], is now being tested in HFpEF (NCT04945460), while bimagrumab, an antibody to ActRII which has beneficial metabolic remodeling and antifibrotic effects[174,175], is being tested in obesity/cardiometabolic disease (NCT05616013).